Figure 2.
Identification of CH genes associated with high risk of hematologic malignancy. (A) We evaluated 166 genes representing the union of 99 genes previously implicated in hematologic malignancy (CH-PD, M-CHIP, and L-CHIP)10,28 and 131 genes mutated at least 40 times in our dataset (observed in ≥∼1 per 1000 individuals). We built cause-specific Cox hazard models with Firth penalized likelihood including adjustments for gender, age, and solid cancer type for all genes and identified 9 with significantly increased hazard rate of hematologic malignancy based on false discovery rate (FDR) < 0.1. (B) HR and 95% CI for high risk CH genes (red, top) and selected comparators that did not meet high risk criteria (blue, bottom). (C) MCAs were divided into an alarm group involving 5/7/17 and an “other” group that did not involve these chromosomes. HRs for MCAs were calculated using the same models described earlier.

Identification of CH genes associated with high risk of hematologic malignancy. (A) We evaluated 166 genes representing the union of 99 genes previously implicated in hematologic malignancy (CH-PD, M-CHIP, and L-CHIP)10,28 and 131 genes mutated at least 40 times in our dataset (observed in ≥∼1 per 1000 individuals). We built cause-specific Cox hazard models with Firth penalized likelihood including adjustments for gender, age, and solid cancer type for all genes and identified 9 with significantly increased hazard rate of hematologic malignancy based on false discovery rate (FDR) < 0.1. (B) HR and 95% CI for high risk CH genes (red, top) and selected comparators that did not meet high risk criteria (blue, bottom). (C) MCAs were divided into an alarm group involving 5/7/17 and an “other” group that did not involve these chromosomes. HRs for MCAs were calculated using the same models described earlier.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal